Samsung Bioepis and Organon shared that the Food and Drug Administration has designated the Hadlima (adalimumab-bwwd) high- and low-concentration (40 mg/0.4 ml, 40 mg/0.8 ml) autoinjectors and ...

HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations (autoinjector, prefilled syringe, and single-dose vial ...

Switching to Humira biosimilars saved Navitus clients more than $315 million in upfront costs in 2024 and resulted in a 60% reduction in net costs per claim.

TevaU and Alvotech claim first US approval for first biosimilar of AbbVie’s high-concentration Humira, ... (40 mg/0.8 mL or 20 mg/0.4 mL) of Humira. ...

The high-concentration (40 mg/0.4 mL) formulation of prefilled syringe and autoinjector of HADLIMA was approved in 2022. 9 Both low- and high-concentration formulations of HADLIMA have been ...

The FDA has granted interchangeability designation to Hadlima (adalimumab-bwwd) as a biosimilar to Humira. 1 Developed by Samsung Bioepis and commercialized by Organon, the parties’ high- and ...

The report spotlights China’s rapid biopharma advancement, alongside a GLP-1 surge, caution surrounding M&A, and a rise in ...

Humira (adalimumab) and Remicade (infliximab) are prescription drugs used to treat certain inflammatory conditions. Find out how these drugs compare. ... • 40 mg/0.8 mL: 100 mg per vial: Dose: ...

The Food and Drug Administration has granted an expanded interchangeable designation for Celltrion’s Yuflyma (adalimumab-aaty), now including prefilled syringe (40mg) and autoinjectors (40mg and ...

The FDA’s designation, which allows pharmacists to substitute HADLIMA™ for Humira® without prescriber consultation according to state pharmacy laws, follows a previous interchangeability ...

AbbVie combines high yield, strong growth from Rinvoq and Skyrizi, and a solid pipeline to support dividends and returns.